Overall, fascin immunoreactivity was detected in 196 out of 220 (89%) NSCLC, including 75 out of 96 (78%) adenocarcinomas, 114 out of 116 (98%) squamous cell carcinomas, five out of 6 (83%) large cell carcinomas, and the two adenosquamous carcinomas investigated (χ2=22.4, P<0.001). This evidence concerns the gene FSCN1 and adenosquamous carcinoma.